CVS suspends sales of Zantac brand and generic heartburn drug during safety review

[October 01, 2019]  (Reuters) - CVS Health Corp said on Saturday it will discontinue sales the popular Zantac heartburn treatment and its own generic ranitidine products from its pharmacies after traces of a known carcinogen were found in some of the products by the U.S. Food and Drug Administration.

The FDA said earlier this month that some of the pills contained small amounts N-nitrosodimethylamine (NDMA), which has also been found in some widely used blood pressure medicines, leading to shortages of those drugs.

CVS said the move to suspend sales of the over-the-counter heartburn drug was taken out of caution while the FDA continues to review if low levels of NDMA in ranitidine - the active ingredient in Zantac - poses a health risk to patients.

"Zantac brand products and CVS brand ranitidine products have not been recalled, and the FDA is not recommending that patients stop taking ranitidine at this time," CVS said http://bit.ly/2lV3rNr in a statement.

Novartis AG's Sandoz unit said last week it was halting distribution of Zantac in all its markets, including the United States and Canada, following safety review of the drug by U.S. and European drug regulators.

(Reporting by Sathvik N in Bengaluru; Editing by Bill Berkrot)

[© 2019 Thomson Reuters. All rights reserved.]

Copyright 2019 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.